Mounjaro Year 2: The Maintenance Question.

Why Year 2 is the real test

The first 12 months of Mounjaro are dominated by a single project: lose the weight. Goals are concrete, the dose escalates on a schedule, you see the scale move, and the decisions are mostly executional. Year 2 is different. The weight loss has slowed or stopped, your body has begun to defend its new set point, and the question is no longer “am I losing?” — it’s “how long do I keep doing this?”

This is where most patients flinch. The honest answer is that obesity is now framed by mainstream endocrinology as a chronic, relapsing condition that responds to ongoing pharmacotherapy — similar to hypertension or hyperlipidemia. You don’t treat high blood pressure for 12 months and stop. The same framing applies to GLP-1 therapy for weight management.

But the framing alone doesn’t answer the practical question of how. Continuing the full 15mg dose indefinitely is one answer. Stepping down to 5mg is another. Cycling on and off is a third. They have different evidence, different costs, and different risks. Let’s walk through what we know.

What the SURMOUNT-4 data actually shows

The SURMOUNT-4 trial is the only large randomized study designed specifically to answer the question of what happens when you stop tirzepatide after losing weight on it. Patients first lost an average of 21% of their body weight over a 36-week run-in on tirzepatide. They were then randomized to either continue tirzepatide or switch to placebo for an additional 52 weeks.

This is the strongest evidence available for continued therapy. The biology is consistent: once you stop the drug, appetite signaling that had been suppressed returns to baseline, and most patients eat more again. Without a deliberate lifestyle change, the weight follows the appetite.

That said, the trial design used the full tirzepatide dose vs complete stop. It does not directly answer whether stepping down to a lower maintenance dose works similarly to staying on the full dose. That question is being studied; clinical practice has run ahead of trial data here, and many patients do well on lower maintenance doses.

Three maintenance strategies (with trade-offs)

This is the matrix we work through with each patient at the 12-month consultation. There is no universally correct choice — your personal answer depends on weight stability, side effect profile, lifestyle confidence, and budget.

What we actually see in our patients

Across our maintenance-phase patients (12+ months on tirzepatide), the rough distribution we observe is:

• About 50% step down to a lower maintenance dose (5mg or 7.5mg) and maintain weight stably for years on that dose.
• About 30% continue at their weight-loss dose, often because they have additional weight goals or because their appetite signaling is strong enough that the lower doses don’t hold them.
• About 15% pulse-cycle successfully with strong lifestyle habits.
• About 5% taper off entirely. Of these, about half maintain weight loss for at least 1 year; the other half regain significantly and restart.

These are not strict numbers from a study — they reflect what we observe in clinic. The point is that “maintenance” is not one thing; it’s a spectrum of choices, and your physician’s role is to help you pick the one most likely to work given your specific profile.

The 5-year cost view

For US cash-pay patients, the 5-year cost difference between staying in the US and using Japan supply is significant enough that it changes the entire framing of long-term therapy. Here are the three scenarios laid out.

The two effects compound: step-down reduces the medication share, and Japan supply reduces the per-month cost. The Year 1 full-dose period costs a lot more than the Year 2-5 maintenance period in absolute dollars. For patients planning to be on Mounjaro for the long haul, this changes the financial conversation entirely.

Trip cadence: every 6 months vs once a year

Most maintenance-phase patients settle on one of two trip patterns:

Pattern A: Twice-yearly trips (every 6 months)

Each trip yields a 6-month supply (sometimes 5 months of medication plus 1 month buffer). Pros: smaller carry-back quantity per trip (no Yakkan Shoumei needed when entering Japan with US-prescribed supply), shorter time between consultations to adjust dose if needed, two opportunities per year to combine with vacation or business travel. Cons: doubles the flight and hotel cost share.

Pattern B: Once-yearly trip (12-month supply)

One trip yields a 12-month supply. Pros: lowest total trip cost (one set of flights and hotel), maximum reduction in overall annual spend. Cons: 12-month supply requires a Yakkan Shoumei import certificate to bring back to the US, and means a longer gap between physician consultations. Best for patients with very stable weight and dose.

Most of our long-term US patients prefer Pattern A (twice-yearly) because they enjoy the Japan visits and like the shorter consultation cycles. Pattern B is more cost-optimized but operationally heavier per trip.

Lifestyle scaffolding in maintenance phase

Throughout this guide we’ve framed Mounjaro as a chronic therapy. That doesn’t mean “medication does all the work.” In our clinic, every maintenance consultation includes a focused conversation about the lifestyle scaffolding underneath the drug — because that’s what determines whether your maintenance strategy is durable.

The three pillars we keep checking

• Protein and resistance training. Maintaining lean muscle mass during sustained caloric reduction matters more than most patients realize. We typically target 1.6-2.0g protein per kg of lean body mass, plus 2-3 resistance training sessions weekly. Patients who skip this lose more muscle and develop a lower resting metabolic rate, which makes long-term maintenance harder.
• Sleep and stress. Cortisol-driven appetite reasserts itself when sleep drops below 6.5 hours or chronic stress is high. Even on Mounjaro, patients who sleep poorly tend to drift upward in weight. This is one of the first things we screen for when a maintenance patient reports unexpected regain.
• Food quality and reflection. Mounjaro suppresses quantity, but quality matters more during maintenance. We work with patients on Mediterranean-style or high-fiber eating patterns — not as a strict diet, but as a framework that supports the metabolic effects of the medication.

The clinical effect of Mounjaro is real, but the most successful maintenance patients are the ones who used the year of weight loss to develop the habits that now hold their new weight even if the medication ever stops being available.

Off-ramp planning (if you want to taper)

Some patients eventually decide they want to come off Mounjaro entirely. This is reasonable, and it is possible to do successfully — but it requires planning.

The taper protocol we typically use

1. Establish stable maintenance for 6+ months at your lowest effective dose before considering taper.
2. Drop dose by half (e.g., 5mg → 2.5mg) and hold for 12 weeks. Watch weight, appetite, and mood.
3. If stable, drop to 2.5mg every other week for 8 weeks. This is functionally a slow weaning.
4. Stop entirely. Monitor weight monthly for 12 months.
5. Restart if regain exceeds 5-10% of stabilized weight. Don’t wait for total regain — restarting earlier is easier than restarting late.

Side effects in Year 2 and beyond

The good news: side effects almost universally diminish by Year 2. The initial nausea, GI upset, and fatigue that dominate Months 1-3 are largely gone by Month 6, and minimal by Month 12. At maintenance dose (5mg or 7.5mg), most patients report very few subjective side effects.

The ones that can persist or appear later

• Constipation. Mild but persistent in some patients. Usually managed by fiber and hydration.
• Gallbladder issues. There is a small but real elevated risk of gallstones across the GLP-1 class, particularly during rapid weight loss. Risk decreases at maintenance dose. Symptoms warrant prompt evaluation.
• Mild muscle loss markers. If you haven’t kept up resistance training, you may notice decreased strength or stamina. This responds to training, not to dose change.
• Mood changes. Some patients report mild mood flattening on chronic GLP-1 use. The mechanism isn’t fully established. If you notice this, mention it at your next consultation — dose or strategy may need adjustment.

Long-term safety data continues to accumulate. So far, tirzepatide’s long-term profile looks favorable, but the absolute body of evidence for 5+ year exposure is still building. Most endocrinologists believe the benefits substantially outweigh the risks for appropriately selected patients, but this is a conversation worth having with your physician on each annual review.

FAQ